Dostarlimab for early-stage MMR deficient endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stage 1, grade 1 or 2 endometrioid endometrial cancer that is MMR deficient (a specific type of cancer cell).
- You want to keep your uterus or are not a candidate for hysterectomy.
- You are generally well enough to be up and about (ECOG score 0-2).
- You have adequate organ function (kidneys, liver, blood counts) and no signs of cancer spread outside the uterus.
- You are not pregnant and willing to use effective contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab (an immunotherapy) given before surgery for early-stage endometrial cancer that has a specific genetic feature (MMRd/MSI-H). The goal is to see if the drug can shrink or eliminate the cancer before standard surgery.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This study tests a drug called dostarlimab for people in India whose endometrial cancer has come back or spread and has a specific genetic profile (dMMR/MSI-H). It may be an option if platinum-based chemotherapy stopped working.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hear when a new Endometrial Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.